TFI International (TFII) Analysts See $0.53 EPS; Cell Therapeutics (CTIC) Has 0.62 Sentiment

June 20, 2017 - By Kurt Siggers

Analysts expect TFI International Inc (TSE:TFII) to report $0.53 EPS on July, 20.They anticipate $0.05 EPS change or 8.62% from last quarter’s $0.58 EPS. T_TFI’s profit would be $48.48 million giving it 12.94 P/E if the $0.53 EPS is correct. After having $0.35 EPS previously, TFI International Inc’s analysts see 51.43% EPS growth. The stock increased 3.00% or $0.8 on June 19, reaching $27.44. About 155,523 shares traded. TFI International Inc (TSE:TFII) has 0.00% since June 20, 2016 and is . It has underperformed by 16.70% the S&P500.

CTI BioPharma Corp. is a biopharmaceutical firm focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The company has market cap of $93.43 million. The Firm is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It currently has negative earnings. It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis.

The stock increased 2.42% or $0.08 on June 19, reaching $3.39. About shares traded. CTI BioPharma Corp (CTIC) has declined 4.09% since June 20, 2016 and is downtrending. It has underperformed by 20.79% the S&P500.

Bvf Inc Il holds 3.63% of its portfolio in CTI BioPharma Corp for 44.80 million shares. Caprock Group Inc. owns 150,000 shares or 0.02% of their US portfolio. Moreover, United Capital Financial Advisers Llc has 0.02% invested in the company for 526,210 shares. The New York-based Jw Asset Management Llc has invested 0.01% in the stock. Nine Chapters Capital Management Llc, a New Jersey-based fund reported 17,200 shares.

Analysts await CTI BioPharma Corp (NASDAQ:CTIC) to report earnings on August, 3. They expect $-0.70 EPS, down 900.00% or $0.63 from last year’s $-0.07 per share. After $-0.71 actual EPS reported by CTI BioPharma Corp for the previous quarter, Wall Street now forecasts -1.41% EPS growth.

Among 3 analysts covering TFI International Inc (TSE:TFII), 0 have Buy rating, 1 Sell and 2 Hold. Therefore 0 are positive. TFI International Inc had 9 analyst reports since January 5, 2017 according to SRatingsIntel. TD Securities maintained it with “Hold” rating and $38 target in Friday, February 17 report. RBC Capital Markets downgraded it to “Sector Perform” rating and $32 target in Thursday, April 13 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: